Natixis Advisors, L.P. Avidity Biosciences, Inc. Transaction History
Natixis Advisors, L.P.
- $53.5 Billion
- Q4 2024
A detailed history of Natixis Advisors, L.P. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 13,577 shares of RNA stock, worth $465,826. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,577Holding current value
$465,826% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RNA
# of Institutions
250Shares Held
107MCall Options Held
224KPut Options Held
161K-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$365 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.23MShares$317 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$296 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$279 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$241 Million0.06% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.79B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...